文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

以急性呼吸衰竭为首发表现的抗合成酶综合征与抗MDA-5皮肺综合征的临床特征与结局:法国多中心回顾性研究

Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study.
PubMed 文献 · Ann Intensive Care · 2018-09-11
一句话结论重症医生应将炎性肌病列为不明原因急性呼吸衰竭的病因;抗MDA-5皮肺综合征院内死亡率84%,显著高于抗合成酶综合征的29%。

该法国35个ICU、2005至2017年的多中心回顾性研究纳入47例因急性呼吸衰竭(ARF)揭示抗合成酶(AS)或抗MDA-5(aMDA-5)综合征的患者。47例中AS 28例(60%)、aMDA-5 19例(40%);89%符合ARDS,其中86%为重度,17%需ECMO。全部患者接受糖皮质激素,72%接受环磷酰胺,15%接受利妥昔单抗,21%接受静脉免疫球蛋白,17%接受血浆置换。ICU死亡率45%、院内死亡率51%;aMDA-5组院内死亡率84%(16/19)显著高于AS组29%(8/28),p=0.001。

要点

  • 47例因ARF揭示AS或aMDA-5综合征的患者中,36%(17例)无肺外表现,不应因缺乏肌无力、皮疹或关节症状而排除炎性肌病。
  • 89%符合ARDS且86%为重度,17%(8/47)需ECMO支持,提示此类患者呼吸衰竭程度重。
  • aMDA-5皮肺综合征院内死亡率84%(16/19),显著高于AS综合征29%(8/28),p=0.001。
  • 全部47例接受糖皮质激素,72%接受环磷酰胺,15%接受利妥昔单抗,21%接受静脉免疫球蛋白,17%接受血浆置换。
  • 入院时C反应蛋白升高(139 [40-208] mg/L)而降钙素原不高(0.30 [0.12-0.56] ng/mL),肌酸激酶≥2倍正常上限者仅20%(9/47)。

适用人群与场景

  • 2005至2017年法国35个ICU收治的、因急性呼吸衰竭揭示抗合成酶(AS)或抗MDA-5(aMDA-5)综合征的成人患者(23例男性,中位年龄60岁,1st-3rd四分位52-69岁,85%无合并症)。
  • 研究纳入的是以ARF为首发表现、入住ICU时揭示AS或aMDA-5综合征的患者,未报告排除标准。

处置流程与药物剂量

  • 47例中100%接受糖皮质激素,72%接受环磷酰胺,15%接受利妥昔单抗,21%接受静脉免疫球蛋白,17%接受血浆置换(原文未报告各药的剂量、途径、频次与疗程)。
  • 17%(8/47)需要体外膜氧合(ECMO)支持。

红旗征与不能漏的情况

  • 36%(17例)无肺外表现,不应因缺少肌肉、关节或皮肤表现而排除AS或aMDA-5综合征。
  • aMDA-5皮肺综合征院内死亡率84%(16/19),显著高于AS综合征29%(8/28),p=0.001。
  • 89%(42例)符合ARDS且其中86%为重度,需警惕快速进展的严重低氧性呼吸衰竭。

研究设计与关键结果

  • 研究类型为13年(2005至2017年)法国35个ICU的多中心回顾性研究,共47例因ARF揭示AS(28例,60%)或aMDA-5(19例,40%)综合征的患者。
  • 肌肉、关节和皮肤表现分别见于11例(23%)、14例(30%)和20例(43%);17例(36%)无肺外表现。
  • C反应蛋白升高至139 [40-208] mg/L,降钙素原为0.30 [0.12-0.56] ng/mL;肌酸激酶≥2倍正常上限者20%(9/47)。
  • 42例(89%)符合ARDS,其中86%为重度,17%(8/47)需要ECMO。
  • ICU死亡率为45%(21/47),院内死亡率为51%(24/47)。
  • aMDA-5组院内死亡16/19(84%),AS组院内死亡8/28(29%),p=0.001。

证据类型、等级与局限

  • 证据类型:多中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,重症医生应考虑将炎性肌病作为不明原因急性呼吸衰竭的病因。
  • 作者指出,肺外表现常缺失(36%无肺外表现),不应以此排除诊断。
  • 作者指出,此类患者死亡率高,尤其是aMDA-5皮肺综合征(院内死亡率84%)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Anti-synthetase (AS) and dermato-pulmonary associated with anti-MDA-5 antibodies (aMDA-5) syndromes are near one of the other autoimmune inflammatory myopathies potentially responsible for severe acute interstitial lung disease. We undertook a 13-year retrospective multicenter study in 35 French ICUs in order to describe the clinical presentation and the outcome of patients admitted to the ICU for acute respiratory failure (ARF) revealing AS or aMDA-5 syndromes.

RESULTS: From 2005 to 2017, 47 patients (23 males; median age 60 [1st-3rd quartiles 52-69] years, no comorbidity 85%) were admitted to the ICU for ARF revealing AS (n = 28, 60%) or aMDA-5 (n = 19, 40%) syndromes. Muscular, articular and cutaneous manifestations occurred in 11 patients (23%), 14 (30%) and 20 (43%) patients, respectively. Seventeen of them (36%) had no extra-pulmonary manifestations. C-reactive protein was increased (139 [40-208] mg/L), whereas procalcitonine was not (0.30 [0.12-0.56] ng/mL). Proportion of patients with creatine kinase ≥ 2N was 20% (n = 9/47). Forty-two patients (89%) had ARDS, which was severe in 86%, with a rate of 17% (n = 8/47) of extra-corporeal membrane oxygenation requirement. Proportion of patients who received corticosteroids, cyclophosphamide, rituximab, intravenous immunoglobulins and plasma exchange were 100%, 72%, 15%, 21% and 17%, respectively. ICU and hospital mortality rates were 45% (n = 21/47) and 51% (n = 24/47), respectively. Patients with aMDA-5 dermato-pulmonary syndrome had a higher hospital mortality than those with AS syndrome (n = 16/19, 84% vs. n = 8/28, 29%; p = 0.001).

CONCLUSIONS: Intensivists should consider inflammatory myopathies as a cause of ARF of unknown origin. Extra-pulmonary manifestations are commonly lacking. Mortality is high, especially in aMDA-5 dermato-pulmonary syndrome.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Vuillard C, Pineton de Chambrun M, de Prost N, et al. Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study. Ann Intensive Care. 2018. PMID: 30203297. doi:10.1186/s13613-018-0433-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。